My Blog List

Monday, January 24, 2022

Type of autoclave and its definition

 

Autoclave Definition

An autoclave is a machine that provides a physical method of sterilization by killing bacteria, viruses, and even spores present in the material put inside of the vessel using steam under pressure. Autoclave sterilizes the materials by heating them up to a particular temperature for a specific period of time. The autoclave is also called a steam sterilizer that is commonly used in healthcare facilities and industries for various purposes. The autoclave is considered a more effective method of sterilization as it is based on moist heat sterilization.
The autoclaving process takes advantage of the phenomenon that the boiling point of water (or steam) increases when it is under high pressure. It is performed in a machine known as the Autoclave where high pressure is applied with a recommended temperature of 250°F (121°C) for 15-20 minutes to sterilize the equipment.

Autoclave classes

1. Class N autoclave

Class N autoclave is the lowest class device. According to European standard EN 13060, since 2004 it can be used only as an auxiliary unit. Sterilizer of this class does not have a vacuum pump (which is present in higher class autoclaves), so only instruments with a solid structure can be sterilized within such device. It is also not possible to sterilize hollow or porous cartridges or sterilize items in packages. Class N sterilizers also do not have an effective drying option, unlike more advanced autoclaves.

2. Class S autoclave

Class S autoclave is an intermediate class between N and B. Within such device we can sterilize more complex instruments, B type batches, except for instruments of capillary construction (A type batches). Class S allows the sterilization of single-packed, multilayer packed and more massive instruments, which cannot be sterilized in class N autoclaves. Autoclaves of this class have a vacuum pump, which makes it possible to completely remove the air from the chamber before starting the sterilization process. However, only a single-stage pre-vacuum is used here; it is less effective than the vacuum used in class B autoclaves.

3. Class B autoclave

Class B autoclaves are the most advanced steam sterilizers. These are certified MEDICAL DEVICES USED IN BEAUTY PARLOURS, tattoo studios, private dental parlours, even in hospitals and large clinics. They also meet all the sanitary-epidemiological requirements. They can sterilize all types of batches, even the most complex ones. Class B autoclave, thanks to fractionated pre-vacuum, completely removes air from the chamber. It is the most effective modern technique of  sterilization of all types of tools.


Positive pressure displacement type (B-type)

  • In this type of autoclave, the steam is generated in a separate steam generator which is then passed into the autoclave.

  • This autoclave is faster as the steam can be generated within seconds.

Negative pressure displacement type (S-type)

  • This is another type of autoclave that contains both the steam generator as well as a vacuum generator.
  • Here, the vacuum generator pulls out all the air from inside the autoclave while the steam generator creates steam.
  • The steam is then passed into the autoclave.
  • This is the most recommended type of autoclave as it is very accurate and achieves a high sterility assurance level.
  • This is also the most expensive type of autoclave.
  • Gravity displacement type autoclave

    • This is the common type of autoclave used in laboratories.
    • In this type of autoclave, the steam is created inside the chamber via the heating unit, which then moves around the chamber for sterilization.
    • This type of autoclave is comparatively cheaper than other types.

    Positive pressure displacement type (B-type)

    • In this type of autoclave, the steam is generated in a separate steam generator which is then passed into the autoclave.
    • This autoclave is faster as the steam can be generated within seconds.
    • This type of autoclave is an improvement over the gravity displacement type.

Saturday, January 22, 2022

History of Virology and Vaccination


The word virus appeared in 1599 and originally meant "venom"

A very early form of vaccination known as variolation was developed several thousand years ago in China. It involved the application of materials from smallpox sufferers in order to immunize others. In 1717 Lady mary    Wortley Montagu observed the practice in Istanbul and attempted to popularize it in Britain, but encountered considerable resistance. In 1796 Edward Jenner developed a much safer method, using cowpox to successfully immunize a young boy against smallpox, and this practice was widely adopted. Vaccinations against other viral diseases followed, including the successful rabies vaccination by Louis Pasteur in 1886. The nature of viruses, however, was not clear to these researchers.

In 1892, the Russian biologist Dmitry Ivanovsky used a Chamberland filter to try to isolate the bacteria that caused tobacco mosaic disease. His experiments showed that crushed leaf extracts from infected tobacco plants remained infectious after filtration. Ivanovsky reported a minuscule infectious agent or toxin, capable of passing the filter, may be being produced by a bacterium.

In 1898 Martinus Beijerinck repeated Ivanovski's work but went further and passed the "filterable agent" from plant to plant, found the action undiminished, and concluded it infectious – replicating in the host – and thus not a mere toxin. He called it contagium vivum fluidum. The question of whether the agent was a "living fluid" or a particle was however still open.

In 1903 it was suggested for the first time that transduction by viruses might cause cancer. In 1908 Bang and Ellerman showed that a filterable virus could transmit chicken leukemia, data largely ignored till the 1930s when leukemia became regarded as cancerous. In 1911 Peyton Rous reported the transmission of chicken sarcoma, a solid tumor, with a virus, and thus Rous became "father of tumor virology" The virus was later called Rous sarcoma virus 1 and understood to be a retrovirus. Several other cancer-causing retroviruses have since been described.

The existence of viruses that infect bacteria (bacteriophages) was first recognized by Frederick Twort in 1911, and, independently, by Félix d'Herelle in 1917. As bacteria could be grown easily in culture, this led to an explosion of virology research.

The cause of the devastating Spanish flu pandemic of 1918 was initially unclear. In late 1918, French scientists showed that a "filter-passing virus" could transmit the disease to people and animals, fulfilling Koch's postulates.

In 1926 it was shown that scarlet fever is caused by a bacterium that is infected by a certain bacteriophage.

While plant viruses and bacteriophages can be grown comparatively easily, animal viruses normally require a living host animal, which complicates their study immensely. In 1931 it was shown that influenza virus could be grown in fertilized chicken eggs, a method that is still used today to produce vaccines. In 1937, Max Theiler managed to grow the yellow fever virus in chicken eggs and produced a vaccine from an attenuated virus strain; this vaccine saved millions of lives and is still being used today.

Max Delbrück, an important investigator in the area of bacteriophages, described the basic "life cycle" of a virus in 1937: rather than "growing", a virus particle is assembled from its constituent pieces in one step; eventually it leaves the host cell to infect other cells. The Hershey–Chase experiment in 1952 showed that only DNA and not protein enters a bacterial cell upon infection with bacteriophage T2Transduction of bacteria by bacteriophages was first described in the same year.

In 1949 John F. EndersThomas Weller and Frederick Robbins reported growth of poliovirus in cultured human embryonal cells, the first significant example of an animal virus grown outside of animals or chicken eggs. This work aided Jonas Salk in deriving a polio vaccine from deactivated polio viruses; this vaccine was shown to be effective in 1955.

The first virus that could be crystalized and whose structure could, therefore, be elucidated in detail was tobacco mosaic virus (TMV), the virus that had been studied earlier by Ivanovski and Beijerink. In 1935, Wendell Stanley achieved its crystallization for electron microscopy and showed that it remains active even after crystallization. Clear X-ray diffraction pictures of the crystallized virus were obtained by Bernal and Fankuchen in 1941. Rosalind Franklin proposed the full structure of the tobacco mosaic virus in 1955 after creating diffraction patterns of TMV "of unprecedented detail and clarity" Also in 1955, Heinz Fraenkel-Conrat and Robley Williams showed that purified TMV RNA and its capsid (coat) protein can self-assemble into functional virions, suggesting that this assembly mechanism is also used within the host cell, as Delbrück had proposed earlier.

In 1963, the Hepatitis B virus was discovered by Baruch Blumberg who went on to develop a hepatitis B vaccine.

In 1965, Howard Temin described the first retrovirus: a virus whose RNA genome was reverse transcribed into complementary DNA (cDNA), then integrated into the host's genome and expressed from that template. The viral enzyme reverse transcriptase, which along with integrase is a distinguishing trait of retroviruses, was first described in 1970, independently by Howard Temin and David Baltimore. The first retrovirus infecting humans was identified by Robert Gallo in 1974. Later it was found that reverse transcriptase is not specific to retroviruses; Retrotransposons which code for reverse transcriptase are abundant in the genomes of all eukaryotes. Ten to forty percent of the human genome derives from such retrotransposons.

In 1975 the functioning of oncoviruses was clarified considerably. Until that time, it was thought that these viruses carried certain genes called oncogenes which, when inserted into the host's genome, would cause cancer. Michael Bishop and Harold Varmus showed that the oncogene of Rous sarcoma virus is in fact not specific to the virus but is contained in the genome of healthy animals of many species. The oncovirus can switch this pre-existing benign proto-oncogene on, turning it into a true oncogene that causes cancer.

1976 saw the first recorded outbreak of Ebola virus disease, a highly lethal virally transmitted disease.

In 1977, Frederick Sanger achieved the first complete sequencing of the genome of any organism, the bacteriophage Phi X 174. In the same year, Richard Roberts and Phillip Sharp independently showed that the genes of adenovirus contain introns and therefore require gene splicing. It was later realized that almost all genes of eukaryotes have introns as well.

A worldwide vaccination campaign led by the UN World Health Organization resulted in the eradication of smallpox in 1979.

In 1982, Stanley Prusiner discovered prions and showed that they cause scrapie.

The first cases of AIDS were reported in 1981, and HIV, the retrovirus causing it, was identified in 1983 by Luc MontagnierFrançoise Barré-Sinoussi and Robert Gallo. Tests detecting HIV infection by detecting the presence of HIV antibody were developed. Subsequent tremendous research efforts turned HIV into the best studied virus. Human Herpes Virus 8, the cause of Kaposi's sarcoma which is often seen in AIDS patients, was identified in 1994. Several antiretroviral drugs were developed in the late 1990s, decreasing AIDS mortality dramatically in developed countries. Treatment that exists for HIV includes a multitude of different drugs collectively termed Highly Active Antiretroviral Therapy (HAART). HAART attacks many different aspects of the HIV virus, effectively reducing its effects below the limit of detection. However, when the administration of HAART is discontinued, HIV will bounce back. This is because HAART does not attack latently infected HIV cells, which can reactivate. 

The Hepatitis C virus was identified using novel molecular cloning techniques in 1987, leading to screening tests that dramatically reduced the incidence of post-transfusion hepatitis.

The first attempts at gene therapy involving viral vectors began in the early 1980s, when retroviruses were developed that could insert a foreign gene into the host's genome. They contained the foreign gene but did not contain the viral genome and therefore could not reproduce. Tests in mice were followed by tests in humans, beginning in 1989. The first human studies attempted to correct the genetic disease severe combined immunodeficiency (SCID), but clinical success was limited. In the period from 1990 to 1995, gene therapy was tried on several other diseases and with different viral vectors, but it became clear that the initially high expectations were overstated. In 1999 a further setback occurred when 18-year-old Jesse Gelsinger died in a gene therapy trial. He suffered a severe immune response after having received an adenovirus vector. Success in the gene therapy of two cases of X-linked SCID was reported in 2000.

In 2002 it was reported that poliovirus had been synthetically assembled in the laboratory, representing the first synthetic organism. Assembling the 7741-base genome from scratch, starting with the virus's published RNA sequence, took about two years. In 2003 a faster method was shown to assemble the 5386-base genome of the bacteriophage Phi X 174 in two weeks.

The giant mimivirus, in some sense an intermediate between tiny prokaryotes and ordinary viruses, was described in 2003 and sequenced in 2004.

The strain of Influenza A virus subtype H1N1 that killed up to 50 million people during the Spanish flu pandemic in 1918 was reconstructed in 2005. Sequence information was pieced together from preserved tissue samples of flu victims; viable virus was then synthesized from this sequence.[The 2009 flu pandemic involved another strain of Influenza A H1N1, commonly known as "swine flu".

By 1985, Harald zur Hausen had shown that two strains of Human papillomavirus (HPV) cause most cases of cervical cancer. Two vaccines protecting against these strains were released in 2006.

In 2006 and 2007 it was reported that introducing a small number of specific transcription factor genes into normal skin cells of mice or humans can turn these cells into pluripotent stem cells, known as induced pluripotent stem cells. The technique uses modified retroviruses to transform the cells; this is a potential problem for human therapy since these viruses integrate their genes at a random location in the host's genome, which can interrupt other genes and potentially causes cancer. 

In 2008, Sputnik virophage was described, the first known virophage: it uses the machinery of a helper virus to reproduce and inhibits reproduction of that helper virus. Sputnik reproduces in amoeba infected by mamavirus, a relative of the mimivirus mentioned above and the largest known virus to date. ]

An endogenous retrovirus (ERV) is a viral element in the genome that was derived from a retrovirus whose genome has been incorporated into the germ-line genome of some organism and is therefore copied with each reproduction of that organism. It is estimated that about 9 percent of the human genome originates from ERVs. In 2015 it was shown that proteins from an ERV are actively expressed in 3-day-old human embryos and appear to play a role in embryonal development and protect embryos from infection by other  

Since the invention of Organ-on-a-chip in 2010s, the engineering approach has found application in the study of many diseases. The approach has also been introduced to virology and chip models are being developed. Examples include the invention of Influenza model by Donald E. Ingber group, the invention of Ebola virus disease model by Alireza Mashaghi group, and the invention of viral hepatitis model by Marcus Dorner group.[35] The organ chip approach will likely replace animal models for human virology.

Tuesday, April 20, 2021

Survival of fittest, And competition in Living behaviour.

Survival of fittest, And competition in Living behaviour.
ये हमे ये बताता है कि किस तरह से जीव जंतुओं को जीवित रहने के लिए, पर्यावरण की स्थिति के अनुसार चेंज होना पडता है। जो Living organisms ऐसा नहीं करते वो  extinct aur Rare Category में आ जाते हैं। कोरोना तो ऐसा कर रहा म्युटेशन पे म्यूटेशन कर के सर्वाइवल के लिय, हर Living organisms का यह Nature है चाहे कोई भी हो। Evolution ,( mutation) इक process है Survival का किसी भी Living organisms का। ऐसा ये भी कर रहा कुछ नया नहीं।  लेकिन हम इन्सान हो के। हम न social, न  physical न । Internal  कुछ नहीं बदलाव कर रहे। न चाहते हैं। ऐसा करना क्यों कि हम काफी Development कर चुके हैं न। चांद तक चले गए। अब क्या कोई बिगारेग। लेकिन हकीकत ऐसा नहीं है। न कभी होगा।  Survival of fittest, And competition in Living behaviour.  ऐ सत्य है। और ये भी। बाप का भी बाप  होता है। इस लिये हम सब को लड़ना होगा।  इक किसी community को बचाने के लिए उस पुरी community को लड़ना पड़ता है। हमें खुद को बचाना है तो । हमें ख़ुद ही लड़ना होगा। Government कोई भगवान नहीं है। वो भी हमारे ही Community के लोग है। हमें खुद में बदलाव लाना होगा। नहीं तो कहीं ऐसा न हो कि हम इक इक कर के extinct aur Rare species बन जाये। लाखो दशकों से मानव से जीतता आया है। हर nature ke competition me. Intraspecific Competition. हो  या inter specific competition, Human इससे भी जीत लेगा। ये तभी होगा situation aur environment ke हिसाब से हम chage honge| आज के condition के हिसाब से  हम मास्क लगाएंगे। Social distence bnayenge. Internal to  तो ne system  fight kar rha. external to Hum hi karenge|  नहीं तो वो दीन दुरे नहीं। जुब हम विलुप्त और दुर्लभ प्रजाति। के लिस्ट में चलें जायेंगे।  फिर other Living organisms बतायेगा अपने बच्चों से कि इस समय की बात है। Human रहते थे इस धरती पर 😄😄😄  it's my own thoughts. Man se nhi likhe hai.  Man se likha padne ke liye. Go to my other Blog 😊😊😄😄👉 science and technology

Thursday, April 9, 2020

Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug

Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug




Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug

Abstract

The antimalarial agents chloroquine and hydroxychloroquine have been used widely for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action distinguishes them from glucocorticoids and nonsteroidal antiinflammatory agents. Chloroquine and hydroxychloroquine increase pH within intracellular vacuoles and alter processes such as protein degradation by acidic hydrolases in the lysosome, assembly of macromolecules in the endosomes, and posttranslation modification of proteins in the Golgi apparatus. It is proposed that the antirheumatic properties of these compounds results from their interference with "antigen processing" in macrophages and other antigen-presenting cells. Acidic cytoplasmic compartments are required for the antigenic protein to be digested and for the peptides to assemble with the alpha and beta chains of MHC class II proteins. As a result, antimalarials diminish the formation of peptide-MHC protein complexes required to stimulate CD4+ T cells and result in down-regulation of the immune response against autoantigenic peptides. Because this mechanism differs from other antirheumatic drugs, antimalarials are well suited to complement these other compounds in combination drug therapy.

How to act on malaria

Dosage Forms & Strengths

tablet

  • 200mg

Malaria

Prophylaxis

  • Indicated for prophylaxis of malaria in geographic areas where chloroquine resistance is not reported
  • 400 mg (310 mg base) PO weekly, starting 2 weeks before exposure and continued for 4 weeks after departure from endemic area OR
  • Weight-based dosing: 6.5 mg/kg (5 mg/kg base) PO once weekly, not to exceed 400 mg (310 mg base), starting 2 weeks before exposure and continued for 4 weeks after leaving the endemic area  

Acute treatment

  • Indicated for treatment of uncomplicated malaria due to P falciparum, P malariae, P ovale, and P vivax
  • 800 mg (620 mg base) PO, then 400 mg (310 mg base) PO at 6 hr, 24 hr, and 48 hr after initial dose
  • Weight-based dosing: 13 mg/kg (10 mg/kg base), not to exceed 800 mg (620 mg base) followed by 6.5 mg/kg (5 mg/kg base), not to exceed 400 mg (310 mg base), PO at 6 hr, 24 hr, and 48 hr after initial dose  

Rheumatoid Arthritis

Indicated for treatment of acute and chronic rheumatoid arthritis
400-600 mg/day (310-465 mg base/day) PO as a qDay or in BID
When a good response is obtained, reduce dosage by 50% and continue maintenance dose of 200-400 mg/day (155-310 mg base/day) PO as a qDay or in BID; not exceed 600 mg or 6.5 mg/kg (5 mg/kg base) per day, whichever is lower, as the incidence of retinopathy has been reported to be higher when this maintenance dose is exceeded
Use corticosteroids and salicylates in conjunction with hydroxychloroquine; gradually decrease dosage or eliminate after a maintenance dose has been achieved

Systemic Lupus Erythematosus

Indicated for treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus
200-400 mg/day (155-310 mg base/day) PO as a single daily dose or in two divided doses
Doses >400 mg/day are not recommended
Incidence of retinopathy has been reported to be higher when this maintenance dose is exceeded

Coronavirus Disease 2019 (COVID-19) (Off-label)

Data available as of March 24, 2020
Note: Limited data available; no drug is FDA approved to treat COVID-19
Hydroxychloroquine may be considered for use as part of an investigational protocol for patients with COVID-19
Must be read..
https://vinodkumarkushwaha.blogspot.com/

Monday, March 23, 2020

Basic protective measures against the new coronavirus

Basic protective measures against the new coronavirus

Stay aware of the latest information on the COVID-19 outbreak, available on the WHO website and through your national and local public health authority. Most people who become infected experience mild illness and recover, but it can be more severe for others. Take care of your health and protect others by doing the following:

Wash your hands frequently

Regularly and thoroughly clean your hands with an alcohol-based hand rub or wash them with soap and water.
Why? Washing your hands with soap and water or using alcohol-based hand rub kills viruses that may be on your hands.

Maintain social distancing

Maintain at least 1 metre (3 feet) distance between yourself and anyone who is coughing or sneezing.
Why? When someone coughs or sneezes they spray small liquid droplets from their nose or mouth which may contain virus. If you are too close, you can breathe in the droplets, including the COVID-19 virus if the person coughing has the disease.

Avoid touching eyes, nose and mouth

Why? Hands touch many surfaces and can pick up viruses. Once contaminated, hands can transfer the virus to your eyes, nose or mouth. From there, the virus can enter your body and can make you sick.

Practice respiratory hygiene

Make sure you, and the people around you, follow good respiratory hygiene. This means covering your mouth and nose with your bent elbow or tissue when you cough or sneeze. Then dispose of the used tissue immediately.
Why? Droplets spread virus. By following good respiratory hygiene you protect the people around you from viruses such as cold, flu and COVID-19.

If you have fever, cough and difficulty breathing, seek medical care early

Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention and call in advance. Follow the directions of your local health authority.
Why? National and local authorities will have the most up to date information on the situation in your area. Calling in advance will allow your health care provider to quickly direct you to the right health facility. This will also protect you and help prevent spread of viruses and other infections.

Stay informed and follow advice given by your healthcare provider

Stay informed on the latest developments about COVID-19. Follow advice given by your healthcare provider, your national and local public health authority or your employer on how to protect yourself and others from COVID-19.
Why? National and local authorities will have the most up to date information on whether COVID-19 is spreading in your area. They are best placed to advise on what people in your area should be doing to protect themselves.

Protection measures for persons who are in or have recently visited (past 14 days) areas where COVID-19 is spreading

  • Follow the guidance outlined above.
  • Stay at home if you begin to feel unwell, even with mild symptoms such as headache and slight runny nose, until you recover. Why? Avoiding contact with others and visits to medical facilities will allow these facilities to operate more effectively and help protect you and others from possible COVID-19 and other viruses.
  • If you develop fever, cough and difficulty breathing, seek medical advice promptly as this may be due to a respiratory infection or other serious condition. Call in advance and tell your provider of any recent travel or contact with travelers. Why? Calling in advance will allow your health care provider to quickly direct you to the right health facility. This will also help to prevent possible spread of COVID-19 and other viruses.

Preventing the Spread of Infectious Diseases coronavirus

Preventing the Spread of Infectious Diseases

Decrease your risk of infecting yourself or others:.
Written by vinod Kumar kushwaha
                      Msc microbiogist

  • Wash your hands often. This is especially important before and after preparing food, before eating and after using the toilet.
  • Get vaccinated. Immunization can drastically reduce your chances of contracting many diseases. Keep your recommended vaccinations up-to-date.
  • Use antibiotics sensibly. Take antibiotics only when prescribed. Unless otherwise directed, or unless you are allergic to them, take all prescribed doses of your antibiotic, even if you begin to feel better before you have completed the medication.
  • Stay at home if you have signs and symptoms of an infection.Don't go to work or class if you're vomiting, have diarrhea or are running a fever.
  • Be smart about food preparation. Keep counters and other kitchen surfaces clean when preparing meals. In addition, promptly refrigerate leftovers. Don't let cooked foods remain at room temperature for an extended period of time.
  • Disinfect the 'hot zones' in your residence. These include the kitchen and bathroom — two rooms that can have a high concentration of bacteria and other infectious agents.
  • Practice safer sex. Use condoms. Get tested for sexually transmitted diseases (STDs), and have your partner get tested— or, abstain altogether.
  • Don't share personal items.Use your own toothbrush, comb or razor blade. Avoid sharing drinking glasses or dining utensils.
  • Travel wisely. Don't fly when you're ill. With so many people confined to such a small area, you may infect other passengers in the plane. And your trip won't be comfortable, either. Depending on where your travels take you, talk to your doctor about any special immunizations you may need.

Monday, March 16, 2020

What is coronavirus, how does Covid-19 spread and what are the symptoms?








What is coronavirus, how does Covid-19 spread and what are the symptoms?

Written by:: 
vinod Kumar kushwaha 
       Msc Microbiologist
16/3/20




CORONAVIRUS has killed more than 3,400 people to date and infected at least 100,000 others.

But what is coronavirus, how does it spread and what are the disease symptoms?

What is coronavirus?



Coronaviruses are a large family of viruses that can cause infections ranging from the common cold to Severe Acute Respiratory Syndrome (Sars).
The virus attacks the respiratory system, causing pneumonia-like lung lesions.
Some of the virus types cause less serious disease, while others – like the one that caused Middle East Respiratory Syndrome (Mers) – are far more severe.
In 2003 an outbreak of a similar virus, Sars, killed more than 900 around the world within weeks.

What are the symptoms?

Symptoms are similar to a common cold.
They include:
  • a runny nose
  • headache
  • cough
  • fever
  • shortness of breath
  • chills
  • body aches
In most cases, you won’t know whether you have a coronavirus or a different cold-causing virus, such as rhinovirus.
But if a coronavirus infection spreads to the lower respiratory tract (your windpipe and your lungs), it can cause pneumonia, especially in older people, people with heart disease or those with weakened immune systems.
There is currently no vaccine for coronavirus
To help prevent infection, do the same things you do to avoid the common cold such as using alcohol-based anti-bacterial soaps and sprays.
People should also avoid touching their eyes, nose and mouth – and avoid contact with people who are infected.
A coronavirus infection should be treated the same way a cold is treated.
Biting your nails can seriously increase your risk of contracting coronavirus, according to an allergy and infectious diseases specialist.
Here’s what can you do to keep your home safe.

How does coronavirus spread?

Coronavirus is an airborne virus, spread in a similar way to colds and the flu.
It is incredibly contagious and is spread through contact with anything the virus is on as well as infected breath, coughs or sneezes.
This means that anyone who is infected can pass it on to any surface or person they breathe on or touch.

How far has the virus spread so far?

In spite of efforts to contain the virus, it has gone international.
China, Japan, Thailand, Singapore, Hong Kong, South Korea, Australia, Taiwan, Malaysia, US, Germany, Vietnam, Macao, France, UAE, Canada, Italy, UK, India, Philippines, Russia, Nepal, Cambodia, Finland, Nepal, Sri Lanka, Belgium and Sweden have all reported cases.
  • January 31, 2020, the first two cases were reported in the UK.
  • February 6, a third Brit tested positive for coronavirus.
  • February 8, five Britons, including one child, were diagnosed with the virus in France  after coming into contact with a person who had been in Singapore.
  • February 10, it was revealed there were eight cases in the UK.
  • February 12, the first case in London was confirmed bringing the total in UK to nine.
  • February 16, the eight-month-old baby feared to be Britain’s youngest coronavirus victim given all

  • How many people have died from coronavirus?
The global death toll stands at over 3,400.
In China, the majority of deaths have been in the central province of Hubei.







Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug

Mechanism of Action of Hydroxychloroquine as an Antirheumatic Drug Mechanism of Action of Hydroxychloroquine as an Antirheumat...